Indirect treatment comparisons of darolutamide plus docetaxel and androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.

ABSTRACT: Androgen deprivation therapy (ADT) has long been the standard-of-care for metastatic, hormone-sensitive prostate cancer (mHSPC). The addition of docetaxel (DOC) and/or androgen receptor axis-targeted therapies (ARATs) such as darolutamide (DAR), enzalutamide (ENZ), apalutamide (APA), abirateone (ABI), and rezvilutamide (REZ) has been shown to significantly improve overall survival (OS) over standard-of-care in mHSPC, including standard of care plus DOC. We indirectly compared OS and progression-free survival (PFS) of DAR+DOC+ADT against approved comparators in China using Bayesian network meta-analysis. Comparator treatment data derived from published trials (identified via Medline, EMBASE, and Cochrane Library searches) and included ENZ, APA, DOC, ABI, and REZ, each with ADT. Sensitivity

SUBMITTER: Wang H 

PROVIDER: S-EPMC12615611 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature